UNSPSC 51162018: Dextromethorphan/dyphylline/pseudoephedrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.

UNSPSC 51162018 Dextromethorphan/dyphylline/pseudoephedrine is a Commodity code under which state and local governments procure pharmaceutical products and pharmacy services, though the recent opportunities reflect a mismatch between the code's nominal scope and actual buying activity. The two recent solicitations tagged to this code involve naloxone and drug deactivation systems procurement for community health support, and on-site pharmacy services management for a county health center serving employee and retiree populations—neither directly aligns with the code's specific pharmaceutical ingredient designation. State and local issuing bodies under this code include county government purchasing offices and county health departments, with at least Seminole County, Florida and Hall County, Georgia appearing as recent active buyers.

Geographic activity centers on Florida and Georgia based on posted opportunities. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, with a response deadline of July 26, 2023, and an initial two-year contract term plus one-year renewal option. Hall County, Georgia issued RFQ/P #47-010 in May 2026 for on-site pharmacy services at the Hall County Government Family Health Center Clinic in Gainesville, serving approximately 3,005 eligible individuals across multiple insurance plans, with responses due June 4, 2026, and a one-year initial term beginning January 1, 2027, with four optional one-year renewals. Both procurements require E-Verify compliance and specified insurance coverage. The code shows limited recent relevant activity; the opportunities posted appear misclassified relative to the code's defined pharmaceutical ingredient scope.